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Objective: Endothelial cells express the ectoenzyme ectonucleoside adenosine triphosphate diphosphohydro-
lase, an apyrase that inhibits vascular inflammation by catalyzing the hydrolysis of adenosine triphosphate and
adenosine diphosphate. However, ectonucleoside adenosine triphosphate diphosphohydrolase expression is
rapidly lost following oxidative stress, leading to the potential for adenosine triphosphate and related purigenic
nucleotides to exacerbate acute solid organ inflammation and injury. We asked if administration of a soluble re-
combinant apyrase APT102 attenuates lung graft injury in a cold ischemia reperfusion model of rat syngeneic
orthotopic lung transplantation.
Methods: Male Fisher 344 donor lungs were cold preserved in a low-potassium dextrose solution in the presence
or absence of APT102 for 18 hours prior to transplantation into syngeneic male Fisher 344 recipients. Seven
minutes after reperfusion, lung transplant recipients received either a bolus of APT102 or vehicle (saline
solution). Four hours after reperfusion, APT102- and saline solution–treated groups were evaluated for lung graft
function and inflammation.
Results: APT102 significantly reduced lung graft extracellular pools of adenosine triphosphate and adenosine
diphosphate, improved oxygenation, and protected against pulmonary edema. Apyrase treatment was associated
with attenuated neutrophil graft sequestration and less evidence of tissue inflammation as assessed by myeloper-
oxidase activity, expression of proinflammatory mediators, and numbers of apoptotic endothelial cells.
Conclusions: Administration of a soluble recombinant apyrase promotes lung function and limits the tissue
damage induced by prolonged cold storage, indicating that extracellular purigenic nucleotides play a key role
in promoting ischemia–reperfusion injury following lung transplantation.
Cardiothoracic Transplantation Sugimoto et alIschemia–reperfusion injury (IRI) continues to be a major
postoperative complication following lung transplantation
and is linked to shortened graft survival.1 A common feature
of lung graft IRI is increased vascular permeability and mi-
crovascular damage.2 Central to the development of IRI is
adhesion and eventual sequestration of activated leukocytes
through disrupted endothelium. Vascular endothelial cells
(ECs) are a major target of preservation damage and have
been implicated in microcirculatory disturbances posttrans-
plantation.3 Upon activation, quiescent EC are capable of
altering the anticoagulant surface phenotype to one that is
prothrombotic, leading to vascular occlusion. EC can inter-
act with complement, chemokine, and humoral components.
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spond to cytokines, present alloantigen or xenoantigen, thus
modulating local immune reactions at inflammatory sites.
Neutrophil sequestration and activation, in particular, seem
to play a key role in vascular injury through EC adhesion-
dependent release of inflammatory mediators such as tumor
necrosis factor (TNF)-a as well as proteases and reactive ox-
ygen species.4 The functional significance of vascular injury
is well documented, but the mechanisms that initiate the pro-
cess remain unclear.
Previous work has shown that extracellular adenosine tri-
phosphate (ATP) and adenosine diphosphate (ADP) are early
stimulators of inflammatory responses by ECs.5 Interest-
ingly, ATP and ADP are released in high concentrations by
activated ECs and platelets following aggregation on endo-
thelium.6 In turn, this activity further catalyzes additional
platelet aggregation, leading to microthrombus formation
and the eventual worsening of endothelial injury.5 Extracel-
lular purigenic nucleotides can also directly stimulate
inflammatory responses in ECs themselves as well as in mac-
rophages and neutrophils through engagement of purigenic
nucleotide receptors that stimulate the expression of inflam-
matory mediators and leukocyte adhesion molecules.7-9
The proinflammatory effects mediated by ATP and ADP
release are negatively regulated by CD39 (ectonucleosidegery c September 2009
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XAbbreviations and Acronyms
ADP ¼ adenosine diphosphate
ATP ¼ adenosine triphosphate
BAL ¼ bronchoalveolar lavage
CD39 ¼ ectonucleoside triphosphate
diphosphohydrolase-1
EBD ¼ Evans blue dye
EC ¼ endothelial cell
ELISA ¼ enzyme-linked immunosorbent assay
IgG ¼ immunoglobulin G
IL-1b ¼ inteleukin-1b
IRI ¼ ischemia–reperfusion injury
MIP-2 ¼ macrophage inflammatory protein-2
MPO ¼ myeloperoxidase
PBS ¼ phosphate-buffered saline
TNF-a ¼ tumor necrosis factor-a
TUNEL ¼ terminal deoxynucleotidyl transferase
dUTP nick end labeling
triphosphate diphosphohydrolase-1), an apyrase that is
highly expressed on the EC membrane.10,11 CD39, through
its intrinsic apyrase activity, rapidly hydrolyzes extracellular
ATP and ADP to adenosine monophosphate and ultimately
adenosine. Interestingly, CD39 activity is quickly lost fol-
lowing oxidative stress.10 Moreover, CD39-deficient mice
are significantly more susceptible to heart, intestinal, and
kidney IRI induced by arterial occlusion.12-14 In all of these
cases, organ injury is associated with increased vascular per-
meability, suggesting a critical role for apyrases in maintain-
ing graft homeostasis following reperfusion after periods of
warm ischemia. However, it is not clear if maintaining apy-
rase activity in solid organs following cold ischemia, as is
necessary for organ preservation and storage during the pro-
cess of transplantation, is protective against IRI.
As duration of cold ischemia time has been linked to graft
survival, we asked if augmentation of CD39 enzymatic ac-
tivity via the infusion of a recombinant soluble apyrase,
APT102, attenuates rat lung graft IRI following prolonged
cold storage and syngeneic orthotopic lung transplantation.1
Here we show for the first time that supplementing apyrase
activity in a solid organ graft following prolonged cold is-
chemia improves graft function and attenuates inflammation
in the perioperative reperfusion period. APT102-treated
lung graft recipients were significantly less susceptible to
pulmonary edema and had better lung graft function as com-
pared with recipients treated with a saline vehicle.
MATERIALS AND METHODS
Animals and Reagents
Fischer 344 rats (Harlan SpragueDawley, Inc, Indianapolis, Ind),weighing
250 to 300 g, were used in all experiments. The Animal Studies Committee at
Washington University School of Medicine approved all animal procedures.The Journal of Thoracic and CAnimals received humane care in compliance with the ‘‘Principles of Labora-
tory Animal Care’’ formulated by the National Society for Medical Research
and the ‘‘Guide for the Care and Use of Laboratory Animals’’ prepared by the
National Academy of Sciences and published by the National Institutes of
Health. APT102, a recombinant soluble form of the human ecto-ATP diphos-
phohydrolase CD39L3, was a gift from APT Therapeutics (St Louis, Mo).
Orthotopic Left Lung Transplantation and APT102
Treatment
To conduct orthotopic left lung transplantation, we used a previously
described cuff technique.15 In brief, after general anesthesia with intra-
peritoneal pentobarbital (65 mg/kg), mechanical ventilation, systemic
heparinization (300 U), and median laparosternotomy, donor rat lungs
were flushed through the main pulmonary artery with 20 mL of cold
(4C) low-potassium dextran glucose solution at 20 cm H2O pressure. In
APT102-treated groups, 0.1 mg/L APT102 was added to the cold preserva-
tion medium. The heart–lung block was then removed with the lungs
inflated at end-tidal volume. The left lung graft was isolated, prepared,
and stored in low-potassium dextran glucose at 4C until transplantation.
After 18 hours of cold preservation, recipient animals were anesthetized
and intubated with a 14-gauge catheter, and we performed a left thoracot-
omy. The pulmonary vessels and bronchus were anastomosed with a stan-
dard cuff technique. In the sham group, rats received anesthesia and
thoracotomy alone. In APT102-treated groups, recipients received treatment
intravenously through the internal jugular vein 7 minutes after graft reperfu-
sion. In dose–response studies, APT102 was administered at a dose of 0.07,
0.22, or 0.66 mg/kg of recipient weight. In all other studies, APT102 was ad-
ministered at a dose of 0.66 mg/kg of recipient weight. In the vehicle-treated
groups, rats received a saline bolus 7 minutes after reperfusion.
Functional Assessment of Transplanted Lung Grafts
The function of the left lung was assessed 4 hours after transplantation.
Rats in each group were reanesthetized with pentobarbital. After tracheos-
tomy, the animals were mechanically ventilated with 100% oxygen, and
we performed a laparosternotomy. The right hilar structures were clamped
to isolate the left lung graft. The animalswere ventilated for 5minutes at a tidal
volume of 1.5 mL, a respiratory rate of 100 breaths/min, and 1.0 cm H2O of
positive end-expiratory pressure. Arterial blood gas analysis was performed
with blood samples obtained from the ascending aorta. The lungs were
flushed with 20 mL of cold (4C) saline solution, and the lung graft was
excised and divided into 3 separate sections. The upper and middle sections
were snap frozen. The upper section was used for enzyme-linked immunosor-
bent assay (ELISA) and the middle section was used for myeloperoxidase
(MPO) assay. The lower section was weighed, dried at 70C for 48 hours,
and then reweighed for calculation of the wet-to-dry ratio.
Real-Time Polymerase Chain Reaction
Total RNA was isolated by Trizol (Sigma, St Louis, Mo) from lung
tissue in accordance with manufacturer’s recommendations and reverse
transcribed and amplified using QuantiTect SYBR RT-PCR kit (Qiagen,
Valencia, Calif) and primer sets (Qiagen) specific for Rattus norvegicus
Entpd2 (CD39) and the housekeeping gene Rn18s (18sRNA). Reverse-tran-
scriptase polymerase chain reaction was carried out on a Bio Rad ICycler for
30minutes at 50C, 15 minutes at 95C, and then 40 cycles of 95C for 15
seconds, 58C for 30 seconds, and 72C for 30 seconds. Levels of intragraft
CD39 were calculated by the DDCT method using 18sRNA as a relative
standard and represented through normalizing CD39 mean expression to
CD39 mean expression in resting lung tissue.
Flow Cytometry
Lungs were digested in a RPMI 1640 solution containing type 2 collage-
nase (0.5 mg/mL) (Worthington Biochemical Corporation, Lakewood, NJ)
and 5 U/mL DNAse (Sigma) for 60 minutes. The digested lung tissue wasardiovascular Surgery c Volume 138, Number 3 753
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Xthen passed through a 70-mm cell strainer and treated with ACK lysing
buffer. Cells were then stained with biotinylated anti-rat CD31 along with
either goat-anti rat E-selectin (R&D Systems, Minneapolis, Minn) or
a goat immunoglobulin control immunoglobulin G (IgG; Ebiosciences,
San Diego, Calif). Samples were then washed and stained with hamster
anti-goat IgG phycoerythrin (Invitrogen, Carlsbad, Calif) and anti-biotin
APC-750 (Ebiosciences) and then analyzed for EC-specific E-selectin ex-
pression on a modified 5-color Becton Dickinson FACS Scan (Becton
Dickinson, Franklin Lakes, NJ) using a CD31þ expression gate.
ATP/ADP Assay
Aliquots from 5.0 mL bronchoalveolar fluid samples were assayed for
ATP and ADP using EnzyLight ATP and ADP assay kits (BioAssay Sys-
tems) in accordance with manufacturer’s recommendations.
Myeloperoxidase Activity
Quantitative MPO activity was determined as previously described.16
Optical density was measured at 460 nm with a spectrophotometer (model
PMQ II; Carl Zeiss, Oberkochen, Germany). Color development was linear
from 5 to 20 minutes. One unit of enzyme activity was defined as 1.0 optical
density unit per minute per milligram of tissue protein at room temperature.
Proinflammatory Cytokine and Chemokine
Measurement
Lung samples were homogenized with T-PER Extraction Reagent
(Pierce, Rockford, Ill). Lung homogenates were centrifuged twice at
10,000 rpm at 4C for 5 minutes, and the supernatants were collected. The
content of TNF-a, inteleukin (IL)-1b, and macrophage inflammatory pro-
tein-2 (MIP-2) were determined by using ELISA kits (BioSource Interna-
tional, Inc, Camarillo, Calif) in accordancewithmanufacturer’s instructions.
Evans Blue Dye Exclusion Analysis
Evans blue dye (EBD) was used to determine lung microvascular perme-
ability. EBD is a sensitive marker for pulmonary edema, and microvascular
dysfunction was quantified by measuring the concentration of EBD within
the lung. EBD solution (100 mg/mL) was prepared in phosphate-buffered
saline solution (PBS; pH 7.4). A separate series of animals (n ¼ 5 each)
had the same surgical procedure and received EBD solution (30 mg/kg) in-
travenously 5 minutes after reperfusion. Four hours after reperfusion, lung
grafts were excised and snap frozen following flushing with 20 mL of PBS.
To extract EBD, the lung tissue was homogenized in 5 mL of formamide.
The homogenate was incubated at 37C for 24 hours and centrifuged at
3500g for 30 minutes. The optical density of the supernatant was measured
at 620 nm. The concentration of EBD was calculated from a standard curve
of EBD–formamide solutions and expressed as milligrams of EBD per gram
of wet lung weight.
Bronchoalveolar Lavage
A separate series of animals (n ¼ 5 each) underwent bronchoalveolar
lavage (BAL) cell counts at the time of sacrifice. The right hilum was
clamped, and the left lung was lavaged twice with saline (3.0 mL per lavage)
through the tracheostomy. BAL fluid was centrifuged at 1500 rpm for
8 minutes. The pellet was resuspended in PBS, and total cell numbers
were counted with hemocytometer using Trypan blue solution (Mediatech,
Herndon, Va) to exclude dead cells. Neutrophil numbers were determined
with a Hemovet HV950FS (CDC Technologies, Oxford, Conn).
Terminal Deoxynucleotidyl Transferase dUTP Nick
End Labeling Assay
Lung specimens harvested 4 hours after reperfusion were perfused with
20 mL isotonic sodium chloride solution and inflation fixed with 20 mLHis-
toChoice (Amresco Inc, Solon, Ohio). Specimens were cut, mounted, depar-
affinized, and then steam treated with Dako target retrieval solution (Dako,754 The Journal of Thoracic and Cardiovascular SurgCarpinteria, Calif) and quenched with 3% hydrogen peroxide. Assessment
of lung cell apoptosis was performed with a terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) kit (Promega, Madison,
Wis) in accordance with manufacturer’s instructions. For quantification of
cell apoptosis, 15 randomly chosen fields were assessed for each group at
a magnification of 3400.
Statistical Analysis
Experimental means are represented with the standard error of the mean.
Statistical analysis to assess significant differences between experimental
groups was performed by using the Student t test.
RESULTS
APT102 Treatment Protects Against Lung Graft IRI
Prior studies have shown that CD39 is required to protect
against solid organ injury and inflammation.5 We asked if
CD39 expression is maintained in lung grafts in a rat model
of lung graft IRI. Lung isografts underwent 18 hours of cold
preservation prior to engraftment and were measured for
intragraft CD39 mRNA 1 or 4 hours after transplantation
(Figure 1, A). Lung grafts from recipients following either
1 or 4 hours of reperfusion had significantly less intragraft
CD39 transcripts relative to either lung tissue preserved
for 18 hours prior to transplantation or lung tissue obtained
from sham-operated rats. As these data suggested that there
is a loss of ectoapyrase activity following lung transplanta-
tion, we next asked if administration of APT102, a soluble
recombinant apyrase, affects lung function and injury in
our model (Figure 1, B). Prior to 18 hours of cold preserva-
tion, either lung grafts were flushed with APT102
(0.1 mg/mL) or vehicle (saline) and then graded amounts
of APT102 or a bolus of saline was administered intrave-
nously 7 minutes following reperfusion. Compared with sa-
line solution–treated recipients, APT102-treated recipients
showed a trend toward better lung function at a dose of
0.22 mg/kg and significant improvement at a dose of
0.66 mg/kg. In accordance with improved lung function,
pulmonary edema trended to lower mean levels at a 0.22
mg/kg dose of APT102 and was significantly attenuated at
a 0.66 mg/kg dose of APT102 (Figure 1, C and D). We
next asked if the APT102-mediated effects on lung graft
IRI were associated with apyrase-specific activity by assess-
ing the concentration of extracellular purigenic nucleotides
(Figure 2). BAL fluid was obtained from saline solution–
treated or APT102-treated recipients and measured for
ATP and ADP levels. Relative to saline solution–treated
lung graft recipients, APT102-treated lung graft recipients
had significantly lower concentrations of both ATP and
ADP in the BAL fluid, indicating that augmenting apy-
rase-specific activity helps preserve lung graft function.
APT102 Treatment Inhibits the Sequestration of
Neutrophils in Lung Grafts
Lung graft IRI is exacerbated by the rapid accumulation
of neutrophils in the airways and lung interstitium.2 Weery c September 2009
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FIGURE 1. APT102 treatment improves lung function and attenuates vascular permeability following lung transplantation. A, Sham lungs, 18-hour cold-
preserved lungs, or lung graft tissue following 1 or 4 hours of reperfusion were assessed for CD39 transcripts by semiquantitative reverse-transcriptase poly-
merase chain reaction and represented as normalized to CD39 levels in resting lung tissue. Sham animals or lung graft recipients treated with saline solution or
indicated amounts of APT102 4 hours postreperfusion were assessed for (B) arterial blood gasses at FiO2 1.0 expressed as a mean PO2 (mm Hg) or (C) mean
wet-to-dry weight ratio. D, Mean percent exclusion of Evans blue dye in sham lungs or lung grafts treated with 0.66 mg/kg APT102 or saline 4 hours post-
reperfusion. Results (A–D) are representative of at least 5 recipients per group and expressed as means  standard errors of the mean. *P<.05 or **P<.01
between indicated groups.therefore asked if APT102-mediated improvement of lung
graft function was associated with the regulation of inflam-
matory cell trafficking into lung grafts. Lung isografts were
cold preserved for 18 hours before engraftment, and total
cell accumulation along with neutrophil numbers in the
BAL were assessed 4 hours after transplantation. APT102-
treated lung graft recipients had significantly fewer cells in
the BAL (Figure 3, A). Additionally, we observed a signifi-
cant decrease in the numbers of neutrophils recovered from
the airways of APT102-treated lung graft recipients as com-
pared with saline solution–treated lung graft recipients
(Figure 3, B). MPO activity, a relative measure of neutrophil
graft tissue infiltration, was also reduced in lung grafts ofAPT102-treated recipients along with the expression of
E-selectin, a critical marker of EC activation that promotes
neutrophil adhesion and sequestration17 (Figure 3, C andD).
APT102 Treatment Attenuates Intragraft
Proinflammatory Cytokine and Chemokine
Synthesis
The reduction in neutrophil accumulation in lung grafts of
APT102-treated recipients suggested attenuation of intra-
graft inflammatory gene expression. In particular, the inflam-
matory cytokines TNF-a and IL-1b promote EC activation,
and the chemokine MIP-2 drives neutrophil chemotaxis into
graft tissue.2 We investigated if APT102 treatment regulatedT
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cific antibodies. Data are represented through a CD31þexpression gate by histograms depicting E-selectin expression (dark lines) relative to an isotype control
(shaded).the intragraft expression of these inflammatory mediators
following 18 hours of cold ischemia and 4 hours engraftment
(Figure 4). APT102 significantly attenuated the intragraft
levels of TNF-a, IL-1b, and MIP-2 protein, suggesting
that augmentation of apyrase activity down-regulates gene
expression associated with tissue inflammation.
APT102 Improves Graft Histopathology and Inhibits
EC Apoptosis
Previous studies have shown that limiting intragraft in-
flammation is important to maintaining graft architec-
ture.18,19 Thus, we inquired if APT102 treatment improved
lung graft histopathology (Figure 5). By hemotoxylin and
eosin stain, APT102-treated recipients had less apparent
alveolar hemorrhage and microvascular injury as compared
with saline solution–treated recipients and only minimal
changes in graft architecture when compared with sham-
operated lungs. These data suggested that the EC barrier
is better preserved in APT102-treated recipients. To exam-
ine this further, we examined lung grafts for the presence of
apoptotic EC by TUNEL stain (Figure 6, A). Consistent
with previous observations in lung grafts subjected to pro-
longed cold ischemia, there were many apoptotic ECs in the
lung graft alveoli of saline solution–treated recipients.20,21
In contrast, in the lung grafts of APT102-treated recipients,
there were significantly fewer apoptotic ECs, indicating
effective protection against vascular injury (Figure 6, B).756 The Journal of Thoracic and Cardiovascular SurDISCUSSION
To our knowledge, this is the first report of the evaluation
of a soluble apyrase in a model of solid organ transplantation
where IRI is initiated by extended cold preservation time. Ex-
tended cold ischemia time has been linked toworse lung graft
survival.1 This issue is clinically relevant as donor lung short-
age often necessitates procurement at geographically distant
sites. Here we report that treatment with a recombinant apy-
rase can attenuate lung graft IRI. APT102 administration just
following reperfusion is effective at improving PaO2, inhibit-
ing pulmonary edema as well as attenuating other markers of
physiologic lung injurywhen comparedwith saline solution–
treated lung transplant recipients.
A key activity of an ectoapyrase is the prevention of
vascular injury through catalyzing the hydrolysis of pro-
inflammatory extracellular purigenic nucleotides.10 The
mechanisms by which apyrase administration protects
against vascular injury are likely to be mediated by at least
two distinct pathways: first, through preventing cell death
as extracellular ATP can promote apoptosis through agoniz-
ing putative type-2X purinergic (P2X7) receptors on EC,
and second, through inhibiting the neutrophil sequestration
by preventing the up-regulation E-selectin.7,22,23 We ob-
served a precipitous loss of CD39 expression along with
a severalfold concentration increase of purigenic nucleotides
in the BAL fluid from lung grafts subjected to prolonged
cold ischemia and 4 hours reperfusion, thus predisposinggery c September 2009
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FIGURE 4. APT102 treatment inhibits inflammatory cytokines and chemokine production. Lung grafts following 4 hours of reperfusion or sham lungs were
homogenized for total protein and assessed for intragraft tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b), and macrophage inflammatory protein-2
(MIP-2) levels by enzyme-linked immunosorbent assay. Results are representative of at least 5 animals per group and expressed as mean  standard error of
the mean. *P< .05 and **P< .01 for indicated groups.the lung to pulmonary vascular injury. Depletion of ATP and
ADP in the BAL fluid after treatment with APT102 indicates
that we were able to increase apyrase activity within lung
grafts. Moreover, supplementation of apyrase activity was
coincident with the prevention of deleterious vascular injury
as evidenced by APT102-mediated attenuation of pulmo-
nary edema, EC apoptosis, and alveolar hemorrhage. Addi-
tionally, we observed that APT102 treatment inhibited the
expression of E-selectin on lung graft ECs. Reduction of
E-selectin on ECs was also associated with significantly
less intragraft accumulation of neutrophils, consistent with
previous work and demonstrating a key role for this vascular
activation marker on neutrophil accumulation in the setting
of lung graft transplantation.24 These data collectively sug-
gest that maintenance of apyrase activity following lung
transplantation is critical to protecting the EC barrier from
injury as well, attenuating mechanisms that promote EC-
driven inflammatory cell sequestration.
Besides directly impacting EC activation and survival,
purigenic nucleotides can also stimulate platelet activation,
leading to aggregation on vascular endothelium.5 In clinical
lung transplantation, platelet accumulation has been ob-
served and continues to be of major concern as it has been
associated with primary graft dysfunction.25,26 Moreover,
accumulation of activated platelets has also been reported
in a rodent syngeneic lung transplantation model following
prolonged cold preservation.27 Lung injury as assessed by
alveolar hemorrhage and pulmonary edema correlated with
the degree of intragraft platelet accumulation. Likewise,we observed alveolar hemorrhage and pulmonary edema
in saline solution–treated recipients in our model of synge-
neic rat lung transplantation. However, treatment at a dose
of 0.66 mg/kg of APT102 was effective at preventing lung
graft alveolar hemorrhage and pulmonary edema. At higher
doses of APT102, however, we noted the gross appearance
of intrapulmonary hematomas in some lung graft recipients
upon necropsy but with no histologic evidence of bleeding
into the alveoli (data not shown). In contrast, there were
no intrapulmonary hematomas in lung graft recipients that
received doses of APT102 of 0.66 mg/kg or less, raising
the possibility that high levels of apyrase activity may pre-
vent the platelet activation necessary for vascular repair or
postsurgical hemostasis.28 Therefore, as with other agents
that potentially inhibit coagulation, careful monitoring of
postoperative bleeding may be required when employing
apyrases to inhibit tissue inflammation in a surgical setting.
Studies are now underway to examine the utility of adminis-
trating several low-dose boluses of APT102 as well altering
APT102 activity by adding moieties to target fibrin deposits
to catalyze the local depletion of extracellular ATP and ADP
pools. It also may be possible to introduce recombinant
apyrases into ex vivo lung perfusion devices; it has been
recently shown that human lung grafts can be maintained
for 12 hours prior to transplantation.29
Although apyrases are thought to principally reduce in-
flammation through attenuating EC functional responses,
their effects could also be mediated through regulating my-
eloid cell inflammatory gene expression in lung grafts.
T
XFIGURE 5. APT102 treatment improves lung graft histopathology. Lung grafts following 4 hours of reperfusion or sham lungs were fixed and sectioned for
histology and stained with hemotoxylin and eosin (H & E).
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XFIGURE 6. APT102 treatment attenuates lung graft endothelial cell apoptosis. Lung grafts following 4 hours of reperfusion or sham lungs were assayed
for terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) reactivity. A, Upper panel: TUNEL-stained slides at 3200 magnification with
inset boxes shown in the lower panelmagnified by33. Lower panel: Examples of TUNEL-positive endothelial cells (ECs) denoted with arrows.B, TUNEL-
positive EC nuclei were counted in randomly selected 3400 fields and expressed as mean  standard error of the mean. **P< .01 for indicated groups
(n ¼ 7/group).Engagement of purigenic receptors on monocytes and mac-
rophages by ATP has been shown to augment IL-1b expres-
sion.8,30,31 Additionally, the generation of adenosine by the
enzymatic degradation of ATP and ADP by apyrases may
also blunt myeloid cell–dependent inflammation. Extracel-
lular adenosine has been shown to inhibit IL-1b and
TNF-a expression in macrophages through agonizing A2B
receptors and to attenuate the oxidative burst in neutrophils
via engagement of A2A receptors.
32 Thus, the additive effect
of the depletion of ATP/ADP and the concomitant genera-
tion of adenosine may synergize to blunt myeloid-dependent
inflammation in lung grafts. In a model of intestinal IRI,
soluble apyrase supplementation reduced injury without
significantly reducing TNF-a, IL-1b, or MPO expression,
suggesting that apyrase can mediate beneficial effects
independently of regulating these genes.12 Although why758 The Journal of Thoracic and Cardiovascular Suapyrase treatment is more effective at reducing inflammatory
mediator expression in lungs than in the intestine is not clear,
one possible explanation is that intestinal bacteria enhance
inflammatory gene expression that is regulated indepen-
dently of ATP/ADP and adenosine, such as through toll-
like receptors.33 To this end, lungs have a comparatively
lower degree of bacterial colonization. Thus, the regulation
of inflammatory gene expression by extracellular ATP/
ADP or the generation of free adenosine could be relatively
more significant in the lung.
In summary, the present study demonstrates for the first
time the beneficial effects of using a soluble apyrase to pre-
vent lung graft IRI. These data extend previous observations
on the use of apyrases in other solid organ models of IRI and
suggest that apyrases inhibit inflammatory responses to lung
grafts. As IRI remains an obstacle to survival in a significantrgery c September 2009
Sugimoto et al Cardiothoracic Transplantationportion of lung transplant recipients, targeting mechanisms
that regulate the generation and stability of extracellular
purigenic nucleotides may have clinical relevance.
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